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c-Ha-ras proteins produced by Escherichia coli inhibited the activities of cathepsins B and L which had been 
partially purified from rat kidney. Furthermore, amino acid sequence homology between c-Ha-ras proteins 
and thiol proteinase inhibitors has been found. 
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1. INTRODUCTION 
Both c-Ha-ras proteins and CAMP-dependent 
protein kinase have been suggested to be involved 
in initiation of two-stage carcinogenesis [l-4]. 
Recently, we have found that the proteolytic 
degradation of CAMP-binding proteins is effec- 
tively inhibited by c-Ha-ras proteins and that the 
degradation of CAMP-binding proteins can 
possibly be carried out by thiol proteinases because 
it is inhibited by leupeptin and antipain (in 
preparation). In the present paper, we report that 
the activities of cathepsins B and L were effectively 
inhibited by c-Ha-ras gene products. Amino acid 
sequence homology between c-Ha-ras proteins and 
thiol proteinase inhibitors also supports the above 
results. 
2. MATERIALS AND METHODS 
2.1. Purification of ras gene products 
Normal human and mutated Ha-ras proteins 
Correspondence address: T. Hiwasa, Division of 
Biochemistry, Chiba Cancer Center Research Institute, 
666-2, Nitona-cho, Chiba 280, Japan 
(~21s) were produced in Escherichia coli with 
plasmids bearing chemically synthesized ras genes. 
p21(Gly-12) and p21(Val-12) are truncated ~21s 
(Met-l to Leu-171) and have glycine and valine, 
respectively, at position 12. Purification of ~21s 
was carried out according to the method of Gibbs 
et al. [5,6] and described in [7]. 
2.2. Assay for cathepsin activity 
Assay for cathepsin activity was carried out ac- 
cording to the method of Barrett and Kirschke [S]. 
Benzyloxycarbonyl-arginyl-arginine 4-methyl-7- 
coumarylamide (Z-Arg-Arg-NMec) and benzyl- 
oxycarbonyl-phenylalanyl-arginine 4-methyl-7- 
coumarylamide (Z-Phe-Arg-NMec) were obtained 
from Peptide Institute Inc. (Osaka, Japan) and 
used as substrates for cathepsins B and L, respec- 
tively. 
2.3. Partial purification of cathepsins 
Cathepsins L and B were partially purified from 
rat kidney according to the method of Barrett and 
Kirschke [8-lo]. A 20-65%-saturation-(NH&- 
SO4 fraction of the homogenate was applied to a 
column of CM-Sephadex C-50 pre-equilibrated in 
buffer A (20 mM sodium phosphate buffer, pH 
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5.8, 1 mM EDTA). After washing with buffer A, 
the column was eluted with 0.2 M KC1 in buffer A 
followed by 0.6 M KC1 in buffer A. The 0.6 M 
KC1 fraction contains cathepsin L [g-lo], and was 
used as a cathepsin L fraction. The purity of 
cathepsin L was approx. 2%. The 0.2 M KC1 frac- 
tion which contains cathepsins B and H was then 
applied to a column of DEAE-cellulose (DE52, 
Whatman) pre-equilibrated in buffer B (20 mM 
sodium phosphate buffer, pH 6.0, 1 mM EDTA). 
The unadsorbed fraction contains cathepsin H 
[lo]. After washing with buffer B, cathepsin B was 
eluted at approx. 0.05 M NaCl. The active frac- 
tions were pooled and used as a cathepsin B frac- 
tion. The purity of cathepsin B was higher than 










3. RESULTS AND DISCUSSION 
We used truncated ~21s instead of full-length 
proteins because the carboxy-terminal region of 
~21 varies among Ha-ras, Ki-rus and N-rus gene 
products and seems to have no essential role except 
anchoring p21 to the plasma membrane [ 1 l-131. 
The activities of partially purified cathepsins B 
and L were inhibited by ~21s. Lineweaver-Burk 
plots showed that ~21s inhibited cathepsins B and 
L non-competitively (fig.1). Ki values of p21s for 
cathepsins B and L were 64 and 22 nM, respective- 
ly. No significant difference of the inhibitory ac- 
tivity between p21(Gly-12) and p21(Val-12) was 
observed (fig. 1). The inhibitory activity for cathep- 
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Fig. 1. Kinetic analysis of the reaction of cathepsins B and L with ~21s. (A) Lineweaver-Burk plots of Z-Arg-Arg-NMec 
concentration against cathepsin B activity in the presence (0,o) or absence (A) of ~21. (0) p21(Gly-12), 0.6 pg/ml; (0) 
p21(Val-12), 0.6 pg/ml. (B) Lineweaver-Burk plots of Z-Phe-Arg-NMec concentration against cathepsin L activity in 
the presence (0,o) or absence (A) of ~21. (0) p21(Gly-12) 0.3 pg/ml; (0) p21(Val-12), 0.3 ag/ml. 
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Fig.2. Comparison of amino acid sequences of c-Ha-ras (p21(Val-12)) with cystatins, including rat cystatin fl [14], rat 
cystatin cy [15], human cystatin B [16], human cystatin A [16], human cystatin C [17], bovine colostrum inhibitor [18], 
chicken cystatin EW [ 19,201, human cystatin S [21], bovine low-M, kininogen [22], and human TPI [23]. The following 
Dayhoff conservative categories [31] were used: C (Cys); A (Ala), G (Gly), P (Pro), S (Ser), and T (Thr); R (Arg), H 
(His), and K (Lys); N (Asn), D (Asp), Q (Gin), and E (Glu); I (Be), L (Leu), M (Met), and V (Val); F (Phe), W (Trp), 
and Y (Tyr). Identical or analogous residues are shaded. Numbers in parentheses represent he amino acid position of 
the beginning of each protein. Gaps, shown by dashes, were introduced for optimal alignment. 
significantly inhibit the activity of trypsin or The region between positions 7 and 22 of c-Ha-rus 
Staphylococcus V8 protease (not shown). also has some homology with cystatins (fig.2). 
Cystatin is a well-known thiol proteinase in- 
hibitor. Many kinds of cystatins have been 
reported [14-231. The amino acid sequence be- 
tween positions 24 and 59 of c-Ha-ru.s is highly 
homologous to those of cystatins (fig.2). This 
region is 61% homologous (19% identical and 
42% conservative substitutions) with that of rat 
cystatinp. The region between positions 41 and 45, 
-Arg Lys Lys-Arg- Gln-Val-Val-, is highly conserved among 
the cystatin superfamily and thought to be a func- 
tional domain. Although the region between posi- 
tions 25 and 46 of p21 had no homology with 
guanine nucleotide-binding proteins such as 
transducin, elongation factor-2, elongation factor- 
Tu, etc. [24], this region is highly conserved among 
the TQS gene family [11,12]. Moreover, it has been 
suggested that this region is indispensable for the 
transforming activity of p21 [25,26]. Therefore, it 
is plausible that thiol proteinase-inhibitor activity 
of p21 may be common among the ras gene family 
and play an important role in its cellular functions. 
In general, Ki values of cystatin for cathepsins L
and H are much lower than that for cathepsin B 
[27,28], while Ki of p21 for cathepsin B (64 nM) is 
slightly higher than that of p21 for cathepsin L 
(22 nM) or that of cystatin for cathepsin B (15 nM 
[29], 16 nM [30]). 
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